Zynerba announces publication of data from Phase 3 CONNECT-FX study

Zynerba Pharmaceuticals announced that the results from the Phase 3 CONNECT-FX study of Zygel for the treatment of behavioral symptoms in children and adolescents with Fragile X syndrome were published in the Journal of Neurodevelopmental Disorders. The paper titled, "A Randomized, Controlled Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome," details how Zygel was well tolerated in patients with FXS and demonstrated efficacy with a favorable benefit risk profile in patients with greater than or equal to90% methylation of the FMR1 gene, in whom gene silencing is most likely, and the impact of FXS is typically most severe. CONNECT-FX was a randomized, double-blind, multinational, 14-week study to evaluate the efficacy and safety of Zygel in children and adolescents aged 3 to 17 years. A total of 212 patients were randomized to 12 weeks of Zygel or placebo, as add-on to standard of care. The trial was conducted at 21 investigational centers in the U.S., Australia and New Zealand. The primary endpoint assessed change in social avoidance measured by the Aberrant Behavior Checklist-Community Edition FXS SA subscale in the full cohort of patients with full mutation FXS, regardless of the FMR1 gene methylation status. Ad hoc analyses assessed efficacy in patients with greater than or equal to90% and 100% methylation of the promoter region of the FMR1 gene, in whom FMR1 gene silencing is most likely. Although statistical significance for the primary endpoint was not achieved in the full cohort, significant improvement was demonstrated in patients with greater than or equal to90% methylation of FMR1, representing 80% of the overall study population. This group also achieved statistically significant improvements in Caregiver Global Impression-Change in SA and Isolation, Irritable and Disruptive Behaviors, and Social Interactions. Similar results were seen in patients with 100% methylation of FMR1, representing 65% of the study population. Zygel was generally well tolerated. All treatment-emergent adverse events were mild or moderate. The most common treatment-related TEAE was application site pain.